New Diamyd Medical-licensed patent issued

Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) announced today that the University of California, Los Angeles, UCLA, has been granted a key patent for a combo treatment for type 1 diabetes with GABA and preproinsulin or an immunogenic fragment thereof. Immunogenic fragments include c-peptide, proinsulin and other insulin molecules. This adds to Diamyd Medical’s patent estate of exclusively licensed intellectual property using GABA for treatment and interception of type 1 diabetes and inflammatory diseases including type 2 diabetes, metabolic syndrome and rheumatoid arthritis.